| Sofia Vazquez Chacon, PT, EMTB, USAR | |
|
Carr 2 Km 87.1, Hatillo, PR 00659 | |
| (787) 466-9466 | |
| (787) 680-7303 |
| Full Name | Sofia Vazquez Chacon |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 25 Years |
| Location | Carr 2 Km 87.1, Hatillo, Puerto Rico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093775454 | NPI | - | NPPES |
| 660632297 | Other | PR | CIGNA |
| 890415 | Other | PR | MMM |
| 660632297 | Other | PR | MCS CLASSICARE |
| 660632297 | Other | PR | MCS |
| 3304248 | Other | PR | ACAA |
| 39425 | Other | PR | PROSAM |
| 5-6763 | Other | PR | TRIPLE-S |
| 6500002 | Other | PR | HUMANA |
| 660632297 | Other | PR | COSVIMED |
| PE4755 | Other | PR | PALIC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 1216 (Puerto Rico) | Primary |
| Provider Name | Eloi Physical Therapy Psc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1821212978 PECOS PAC ID: 5395820443 Enrollment ID: O20090212000005 |
News Archive
Researchers at the Kimmel Cancer Center at Jefferson have identified cancer cell mitochondria as the unsuspecting powerhouse and "Achilles' heel" of tumor growth, opening up the door for new therapeutic targets in breast cancer and other tumor types.
HHS Secretary Kathleen Sebelius announced today that the U.S. Department of Health and Human Services (HHS) is joining with the Ad Council to launch a new nationwide public service advertising (PSA) campaign called "Together We Can All Fight the Flu."
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.
Researchers collected health and injury data during a one-year period on more than 2,500 adults living in Colorado. More than one out of four (26 percent) of the extremely obese male participants reported personal injuries, and more than one out of five (21.7 percent) extremely obese women also reported injuries.
Nymox Pharmaceutical Corporation is pleased to report positive new results from the 48-60 month follow-up study of patients treated with NX-1207 in Study NX02-0014. The initial study, completed in the U.S. in 2006, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days post-treatment with NX-1207 2.5 mg.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sofia Vazquez Chacon, PT, EMTB, USAR P.o. Box 2083, Hatillo, PR 00659-9083 Ph: (787) 466-9466 | Sofia Vazquez Chacon, PT, EMTB, USAR Carr 2 Km 87.1, Hatillo, PR 00659 Ph: (787) 466-9466 |
News Archive
Researchers at the Kimmel Cancer Center at Jefferson have identified cancer cell mitochondria as the unsuspecting powerhouse and "Achilles' heel" of tumor growth, opening up the door for new therapeutic targets in breast cancer and other tumor types.
HHS Secretary Kathleen Sebelius announced today that the U.S. Department of Health and Human Services (HHS) is joining with the Ad Council to launch a new nationwide public service advertising (PSA) campaign called "Together We Can All Fight the Flu."
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.
Researchers collected health and injury data during a one-year period on more than 2,500 adults living in Colorado. More than one out of four (26 percent) of the extremely obese male participants reported personal injuries, and more than one out of five (21.7 percent) extremely obese women also reported injuries.
Nymox Pharmaceutical Corporation is pleased to report positive new results from the 48-60 month follow-up study of patients treated with NX-1207 in Study NX02-0014. The initial study, completed in the U.S. in 2006, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days post-treatment with NX-1207 2.5 mg.
› Verified 1 days ago
Yahira Candelaria, MPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Hc 5 Box 55100, Hatillo, PR 00659 Phone: 939-389-0941 | |
Patricia Rodriguez, MAPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Hc 5 Box 55207, Hatillo, PR 00659 Phone: 787-820-7727 | |
Centro De Terapia Fisica Y Atletica Nueva Vida Psc Physical Therapist Medicare: Medicare Enrolled Practice Location: 462 Atlantic View Buildin Suite 2, Carretera 2 Km 83.5 Marginal Carrizales, Hatillo, PR 00659 Phone: 787-544-6888 Fax: 787-544-6888 | |
Miss Jossymar Perez-gonzalez, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Street. #2 Km 86.6, Hatillo, PR 00659 Phone: 787-201-4912 | |
Misael Francisco Riquelme, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Carr #2 Km 81.5 Bo Carrizales, Hatillo, PR 00659 Phone: 787-915-3000 | |
Ivelisse Millet Santiago, MSPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 462 Atlantic View Building Suite 2, Marginal Carrizales, Hatillo, PR 00659 Phone: 787-544-6888 Fax: 787-544-6888 |